An effective communication between the physician and the patient in an early intervention of hypertension and dyslipidemia

Česká verzia

Authors: Barbora Nussbaumerová
Authors place of work: Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze
Published in the journal: Vnitř Lék 2021; 67(4): 244-248
Category:

Summary

The article summarizes the cornestones of inicitating the pharmacotherapy of hypertension and dyslipidemia. The intervention of dyslipidemia should not be delayed after the intervention of hypertension. The compliance and the adhrence are far from ideal. The physicians should support their patients with an appropriate approach. Vascular age should be used for the explanation of the cardiovascular risk.

Keywords:

hypertension – dyslipidemia – comunication – compliance – adherence – vascular age

Zdroje

1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021–3104.

2. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modifi cation to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.

3. Böhm M, Schumacher H, Laufs U et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013; 166(2): 306– 314. e7. doi: 10.1016/ j.ahj.2013.04.016.

4. Mazzaglia G, Ambrosioni E, Alacqua M et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120(16): 1598– 1605. doi: 10.1161/ CIRCULATIONAHA.108.830299.

5. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381–1391.

6. Olsen MH, Angell SY, Asma S et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016; 388(10060): 2665–2712.

7. Zafarová Z. Zaznělo na 18. kongrese Medicíny pro praxi, Olomouc, 25.–26. září 2020 Využijme cévní věk k motivaci pacientů k preventivní kardiovaskulární léčbě. Med. praxi 2020; 17(5): 336–338.

8. Češka R, Petrák O. Vaskulární věk, Vnitř Lék 2019; 65(12): 770–774.

9. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010t; 31(19): 2351–2358.

10. Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Eff ectiveness of the Heart Age tool for improving modifi able cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015; 22(3): 389–396.

11. Cuende JI. Vascular Age Versus Cardiovascular Risk: Clarifying Concepts Rev Esp Cardiol. 2016; 69(3): 243–246.

12. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713–719.

13. Motlová L, Holub D. Compliance a adherence: spolupráce při léčbě. Remedia 2005(6).